OVGUS - Clinical trial • Breast Cancer Foundation NZ

We're here to help during Covid-19. Find out more here. 


Early Breast Cancer clinical trials for ER+

Updated: April 27, 2021

This study will investigate the feasibility of using oestradiol vaginal tablets for women on adjuvant aromatase inhibitors for breast cancer.

This study will look at if Vagifem Low tablets can treat symptoms like vaginal itching, pain and irritation for women taking aromatase inhibitors after finishing active breast cancer treatment. We hope this study will further medical knowledge and may improve treatment of genitourinary symptoms for women in the future.

Who is it for?

You may be eligible to join this study if you are female, aged 18 and above, have early breast cancer (stage I-III), on an aromatase inhibitor for at least three months and are experiencing genitourinary symptoms.

Study details

All participants in this study receive estradiol vaginal pessaries (Vagifem Low) for 12 weeks (daily application for the first 14 days, then twice a week application for the next ten weeks).

Feasibility/adherence to treatment will be assessed using a participant diary. This study will also assess symptom response, quality of life and sexual function using questionnaires and the effect of this treatment on blood levels of oestrogen.

Full trial information


Campbelltown Hospital, Campbelltown
Concord Repatriation Hospital, Sydney
Nepean Hospital, Sydney
St Vincent's Hospital (Darlinghurst), Sydney


Antonia Pearson

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Early Breast Cancer , Supportive Care

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.